Looking ahead, a key catalyst for Immunic is the expected results from the Phase 2 CALLIPER trial in progressive MS (PMS), anticipated in April 2025. This trial focuses on the annualized rate of ...

H.C. Wainwright analyst Matthew Caufield initiated coverage of Immunic (IMUX) with a Buy rating and $10 price target The firm likes the company’s “comprehensive” neuroprotective and anti-inflammatory ...

Good morning, and welcome to Immunic's Third Quarter 2023 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's call ...

Immunic Inc. (NASDAQ:IMUX) is one of the best penny stocks under $1 to buy now. On June 24, Immunic reported positive long-term open-label extension/OLE data from its Phase 2 EMPhASIS trial. The trial ...

– Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Immunic ( (IMUX)) just unveiled an ...

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology 13.11.2024 / 12:30 CET/CEST The issuer is solely ...

NEW YORK - Immunic, Inc. (NASDAQ: IMUX), a biotech firm specializing in treatments for chronic inflammatory and autoimmune diseases with a market capitalization of $123 million, unveiled positive ...

NEW YORK, April 10, 2025 /PRNewswire/ - Immunic, Inc. (“Immunic” or the“Company”) (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule ...

* SAYS OFFERING OF 2.18 MILLION COMMON SHARES PRICED AT $11.40PER SHARE Source text for Eikon: Further company coverage: Sign up here. Our Standards: The Thomson Reuters Trust Principles. Health ...